Sage Therapeutics (NASDAQ:SAGE) Receives Neutral Rating from Robert W. Baird

Sage Therapeutics (NASDAQ:SAGEGet Free Report)‘s stock had its “neutral” rating reissued by stock analysts at Robert W. Baird in a report issued on Tuesday, Benzinga reports. They presently have a $15.00 target price on the biopharmaceutical company’s stock. Robert W. Baird’s price target would suggest a potential upside of 37.61% from the company’s current price.

A number of other analysts have also commented on the company. TD Cowen decreased their price objective on Sage Therapeutics from $30.00 to $16.00 and set a “buy” rating for the company in a report on Thursday, April 18th. Wedbush restated a “neutral” rating and issued a $24.00 target price on shares of Sage Therapeutics in a research report on Wednesday, April 17th. Baird R W raised Sage Therapeutics to a “hold” rating in a research report on Wednesday, May 29th. Mizuho lowered their price target on shares of Sage Therapeutics from $20.00 to $18.00 and set a “neutral” rating for the company in a research report on Friday, April 26th. Finally, Scotiabank reduced their price target on shares of Sage Therapeutics from $34.00 to $19.00 and set a “sector outperform” rating for the company in a research report on Thursday, April 18th. Two analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $35.05.

Get Our Latest Analysis on Sage Therapeutics

Sage Therapeutics Stock Up 3.0 %

Shares of SAGE stock opened at $10.90 on Tuesday. The company’s fifty day simple moving average is $13.15 and its 200-day simple moving average is $19.12. The firm has a market cap of $655.96 million, a PE ratio of -1.30 and a beta of 0.92. Sage Therapeutics has a 12 month low of $10.19 and a 12 month high of $59.99.

Sage Therapeutics (NASDAQ:SAGEGet Free Report) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.63) by ($0.17). The business had revenue of $7.90 million during the quarter, compared to the consensus estimate of $5.26 million. Sage Therapeutics had a negative net margin of 552.52% and a negative return on equity of 56.81%. The company’s revenue was up 139.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($2.46) EPS. On average, equities analysts predict that Sage Therapeutics will post -6.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sage Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SAGE. Trexquant Investment LP acquired a new position in shares of Sage Therapeutics in the 4th quarter valued at $2,234,000. Vanguard Group Inc. raised its stake in shares of Sage Therapeutics by 3.5% during the 3rd quarter. Vanguard Group Inc. now owns 5,208,002 shares of the biopharmaceutical company’s stock worth $107,181,000 after buying an additional 175,565 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Sage Therapeutics by 3.3% in the third quarter. Wellington Management Group LLP now owns 6,572,260 shares of the biopharmaceutical company’s stock valued at $135,257,000 after purchasing an additional 208,630 shares in the last quarter. Algert Global LLC acquired a new stake in Sage Therapeutics during the 3rd quarter valued at $1,167,000. Finally, Assenagon Asset Management S.A. lifted its holdings in Sage Therapeutics by 1,058.4% in the 1st quarter. Assenagon Asset Management S.A. now owns 156,593 shares of the biopharmaceutical company’s stock valued at $2,935,000 after purchasing an additional 143,075 shares in the last quarter. Hedge funds and other institutional investors own 99.22% of the company’s stock.

About Sage Therapeutics

(Get Free Report)

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.

Further Reading

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.